Clinical trial
Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
NCT00345761 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00345761 |
|---|---|
| Title | Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer |
| Official title | Phase I/II Study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in Advanced and/or Metastatic Colorectal Cancer |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Collaborators | Yakult Honsha Co., LTD Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Oxaliplatin, Capecitabine |
| Enrollment | 64 |
| Start date | Feb 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Jul 1, 2010 |
| First posted | Jun 28, 2006 |
| Last update posted | Aug 16, 2010 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: